表紙：In Silico臨床試験市場の2030年までの予測：治療領域別、フェーズ別、用途別、エンドユーザー別、地域別の世界分析

市場調査レポート

商品コード

1383360

In Silico臨床試験市場の2030年までの予測：治療領域別、フェーズ別、用途別、エンドユーザー別、地域別の世界分析

In Silico Clinical Trials Market Forecasts to 2030 - Global Analysis By Therapeutic Area, Phase, Application, End User and By Geography.

出版日: 2023年11月01日
発行: Stratistics Market Research Consulting
ページ情報: 英文 200+ Pages
納期: 2～3営業日

カスタマイズ可能

価格

PDF (Single User License)

USD 4,150 609,303円

レポートPDFを1名様のみがご利用頂けるライセンスです。PDF内のテキスト等のコピー＆ペーストは可能です。PDFの印刷は1回のみ可能です。印刷したもののご利用はPDFのご利用範囲に準拠します。

PDF (2-5 User License)

USD 5,250 770,805円

レポートPDFを同一事業所（所在地）内の5名までご利用頂けるライセンスです。PDF内のテキスト等のコピー＆ペーストは可能です。PDFの印刷は5回まで可能です。印刷したもののご利用はPDFのご利用範囲に準拠します。

PDF & Excel (Site License)

USD 6,350 932,307円

レポートPDFおよびExcelを同一事業所（所在地）内のすべての方にご利用頂けるライセンスです。PDFおよびExcel内のテキスト等のコピーは可能です。PDFおよびExcelの印刷は5回まで可能です。印刷したもののご利用はPDFおよびExcelのご利用範囲に準拠します。

PDF & Excel (Global Site License)

USD 7,500 1,101,150円

レポートPDFおよびExcelを企業内すべての方に使用頂けるライセンスです。PDFおよびExcel内のテキスト等のコピーは可能です。PDFおよびExcelの印刷は10回まで可能です。印刷したもののご利用はPDFおよびExcelのご利用範囲に準拠します。

価格表記: USDを日本円(税抜)に換算

本日の銀行送金レート: 1USD=146.82円

全表示
概要
図表
目次

概要

サンプル依頼リストに入れる

Stratistics MRCによると、世界のIn Silico臨床試験市場は2023年に32億3,000万米ドルを占め、予測期間中のCAGRは9.4％で成長し、2030年には60億6,000万米ドルに達すると予測されています。

In Silico臨床試験は、仮想臨床試験または計算臨床試験とも呼ばれ、製薬およびヘルスケア業界で使用されるコンピュータベースのモデリングおよびシミュレーションの一形態です。In Silico臨床試験には、臨床試験、医薬品開発、薬物に対する患者の反応など様々な側面をシミュレートするための計算技術や数理モデルが使用されます。In Silico臨床試験は、ヒトまたは動物実験に移行する前に貴重な知見を提供することにより、大規模でコストのかかる物理的試験の必要性を減らし、医薬品開発を加速し、治療戦略を最適化し、患者の安全性を高めることを目的としています。

欧州医薬品庁（European Medicines Agency-European Union）によると、EU/EEAでは毎年4,000件以上の臨床試験が承認されており、そのうち60％は製薬企業が、40％は非商業スポンサーがスポンサーとなっています。

患者の安全性の向上

In Silico臨床試験は、従来の人による臨床試験をコンピューター・シミュレーションに置き換える、あるいは補完することで、医薬品開発に変革をもたらすアプローチです。この方法により、ヒトを対象とした実験的な医薬品試験に伴うリスクが大幅に軽減されます。In Silico試験では、仮想の患者モデルを用いて、起こりうる副作用や薬物相互作用、患者特有の反応を評価することができるため、新薬候補の安全性プロファイルが向上します。さらに、このような試験により、製薬会社は副作用を最小限に抑え、患者にとってより高い安全性を確保するために、医薬品の製剤を改良し、投与量を最適化することができます。製薬業界では患者の安全性が最重要課題であるため、In Silico臨床試験は医薬品開発プロセス全体の安全性を高める強力な手段となり、市場成長と普及の極めて重要な促進要因となっています。

学際的課題

学際的課題は、In Silico臨床試験市場の大きな抑制要因となっています。In Silico臨床試験には、生物学、化学、薬理学、データサイエンス、コンピュータ工学など、多様な分野の専門家が協力する必要があります。これらの分野の知識を効果的に伝達し統合することは複雑であり、誤った解釈やデータの非互換性、誤解を招く可能性があります。このような学際的な課題は、研究開発努力を遅らせ、In Silico手法の採用を妨げ、医薬品開発におけるこの革新的なアプローチの可能性を最大限に引き出すためには、調整と標準化を強化する必要があります。

人工知能と機械学習技術の進歩

人工知能（AI）と機械学習（ML）技術の進歩は、In Silico臨床試験市場に大きなチャンスをもたらします。これらの技術は、患者の反応を予測し、薬剤候補を最適化し、潜在的な副作用を特定することで、in silico臨床試験の精度を高める。さらに、AIと機械学習は新たな治療標的の発見と既存薬の再利用を促進し、調査に必要な時間とコストを削減します。これらの技術が進化を続けるにつれ、In Silico臨床試験市場は、効率性の向上、医薬品開発の成功率の改善、よりオーダーメイドで効果的な治療法の可能性といった恩恵を受け、最終的には製薬業界に革命をもたらすことになります。

標準化されたプロトコルと規制の枠組みの欠如

In Silico試験は計算モデルやシミュレーションに依存しており、普遍的に認められた標準がないため、結果にばらつきや矛盾が生じる可能性があります。さらに、規制機関はIn Silico試験を評価・承認するための明確なガイドラインの確立に苦慮し、その採用が遅れる可能性があります。標準化されたプロトコールや規制がないため、In Silico試験の結果の信頼性や信頼性に懸念が生じ、製薬業界やヘルスケア業界における信頼や受容の妨げとなります。

COVID-19の影響

COVID-19パンデミック危機は、いくつかの業界に壊滅的な影響を与えました。この時期に医薬品開発を支援するためにコンピュータが使用されたことで、In Silico試験市場は顕著な伸びを示しました。学者やバイオテクノロジー、バイオ製薬企業は、コロナウイルス病の蔓延を防ぐための研究開発に集中的に取り組んでいるため、計算モデリングを用いたIn Silico試験の必要性が高まっています。さらに、ウイルスの変異率が上昇していることから、科学者たちはCOVID-19パンデミックの治療法を見つけるために懸命に取り組んでいます。その結果、研究と創薬の重要性が高まり、医療製品の革新と規制当局の認可のためのIn Silico計算モデリングとシミュレーション試験の増加に拍車がかかっています。

予測期間中はオンコロジー分野が最大になる見込み

オンコロジー分野が最大のシェアを占めると推定されます。In Silico臨床試験は、がん治療法の開発を加速するためにコンピューターシミュレーションとモデリングを活用することで、腫瘍学研究に画期的なアプローチを提供します。これらのシミュレーションは、薬剤候補の有効性を評価し、患者の反応を予測し、治療戦略を最適化するのに役立ちます。がんの複雑性と革新的な治療法の緊急性を考えると、がん領域におけるin silico臨床試験は、従来の臨床試験に伴うリスクの軽減だけでなく、コストと時間の節約という点で大きな利点を提供します。このセグメントは、精密医療と個別化がん治療の進歩に極めて重要な役割を果たし、がん患者の転帰改善に希望をもたらします。

予測期間中にCAGRが最も高くなると予想される製薬・バイオテクノロジー企業セグメント

製薬・バイオテクノロジー企業セグメントは、予測期間中に有利な成長を遂げると予測されています。製薬・バイオテクノロジー企業は、創薬・薬剤開発プロセスを合理化するためにIn Silico法を活用しています。In Silico試験では、薬物の挙動を予測し、製剤を最適化し、安全性と有効性を評価するために、コンピュータシミュレーションとモデリングを採用しています。このアプローチは研究開発コストを大幅に削減し、新薬の上市までの時間を短縮します。また、薬剤候補をより効率的に探索できるため、コストと時間のかかる実地試験の必要性を最小限に抑えることができます。さらに、製薬企業やバイオテクノロジー企業は、In Silico臨床試験を活用することで、研究パイプラインを強化し、技術革新を進め、最終的には患者により安全で効果的な治療法を提供することができます。

最大のシェアを占める地域

推定期間中、アジア太平洋地域が最大の市場シェアを占めました。この成長を促進する要因としては、堅調な製薬・バイオテクノロジー産業、大規模で多様な患者集団、支持的な規制環境などが挙げられます。In Silico臨床試験は、薬剤の有効性と安全性を評価するためにコンピュータ・シミュレーションとモデリングを利用するもので、従来の臨床試験に代わる費用対効果に優れた効率的な選択肢を提供します。このアプローチは、医薬品開発プロセスを加速させるだけでなく、コスト削減やヒト試験に伴う倫理的懸念の軽減にもつながります。この技術への投資が増加しているアジア太平洋地域は、In Silico臨床試験の主な拠点となる可能性を浮き彫りにしており、医薬品開発の迅速化と医療成果の向上に貢献しています。

CAGRが最も高い地域：

北米は予測期間中に収益性の高い成長を遂げることが予想されます。北米はIn Silico臨床試験市場において重要な拠点です。この地域は製薬・バイオテクノロジー部門が確立されており、医薬品開発を促進するための革新的なソリューションを絶えず模索しています。In Silico臨床試験は、薬剤の安全性と有効性を評価するためにコンピュータベースのシミュレーションを利用するもので、そのコスト効率とスピードにより人気を集めています。大手製薬企業や最先端の研究機関の存在が、この技術の採用をさらに後押ししています。さらに、北米の規制の枠組みとヘルスケアインフラがin silico臨床試験の成長を支えており、同地域は計算モデリングとシミュレーションを通じて創薬と薬剤開発を推進するリーダー的存在となっています。

無料のカスタマイズサービス：

本レポートをご購読のお客様は、以下の無料カスタマイズオプションのいずれかをご利用いただけます：

企業プロファイル
- 追加市場プレイヤーの包括的プロファイリング（3社まで）
- 主要企業のSWOT分析（3社まで）
地域セグメンテーション
- 顧客の関心に応じた主要国の市場推計・予測・CAGR（注：フィージビリティチェックによる）
競合ベンチマーキング
- 製品ポートフォリオ、地理的プレゼンス、戦略的提携に基づく主要企業のベンチマーキング

北米
- 米国
- カナダ
- メキシコ
欧州
- ドイツ
- 英国
- イタリア
- フランス
- スペイン
- その他欧州
アジア太平洋地域
- 日本
- 中国
- インド
- オーストラリア
- ニュージーランド
- 韓国
- その他アジア太平洋地域
南米
- アルゼンチン
- ブラジル
- チリ
- その他南米
中東とアフリカ
- サウジアラビア
- アラブ首長国連邦
- カタール
- 南アフリカ
- その他中東とアフリカ

第10章主な発展

契約、パートナーシップ、コラボレーション、合弁事業
買収と合併
新製品の発売
事業拡大
その他の主要戦略

第11章企業プロファイル

Certara, Inc.
Insilico Medicine, Inc.
Novadiscovery Sas
Dassault Systemes SE
The AnyLogic Company
GNS Healthcare Inc.
InSilicoTrials
Nuventra Pharma Sciences
Immunetrics Inc.
Abzena Ltd.
Clarivate
Evotec
Aitia
Allucent
Acellera Ltd.

図表

List of Tables

Table 1 Global In Silico Clinical Trials Market Outlook, By Region (2021-2030) ($MN)
Table 2 Global In Silico Clinical Trials Market Outlook, By Therapeutic Area (2021-2030) ($MN)
Table 3 Global In Silico Clinical Trials Market Outlook, By Oncology (2021-2030) ($MN)
Table 4 Global In Silico Clinical Trials Market Outlook, By Cardiology (2021-2030) ($MN)
Table 5 Global In Silico Clinical Trials Market Outlook, By Diabetes (2021-2030) ($MN)
Table 6 Global In Silico Clinical Trials Market Outlook, By Infectious Disease (2021-2030) ($MN)
Table 7 Global In Silico Clinical Trials Market Outlook, By Neurology (2021-2030) ($MN)
Table 8 Global In Silico Clinical Trials Market Outlook, By Hematology (2021-2030) ($MN)
Table 9 Global In Silico Clinical Trials Market Outlook, By Dermatology (2021-2030) ($MN)
Table 10 Global In Silico Clinical Trials Market Outlook, By Other Therapeutic Areas (2021-2030) ($MN)
Table 11 Global In Silico Clinical Trials Market Outlook, By Phase (2021-2030) ($MN)
Table 12 Global In Silico Clinical Trials Market Outlook, By Phase I (2021-2030) ($MN)
Table 13 Global In Silico Clinical Trials Market Outlook, By Phase II (2021-2030) ($MN)
Table 14 Global In Silico Clinical Trials Market Outlook, By Phase III (2021-2030) ($MN)
Table 15 Global In Silico Clinical Trials Market Outlook, By Phase IV (2021-2030) ($MN)
Table 16 Global In Silico Clinical Trials Market Outlook, By Application (2021-2030) ($MN)
Table 17 Global In Silico Clinical Trials Market Outlook, By Drug Development (2021-2030) ($MN)
Table 18 Global In Silico Clinical Trials Market Outlook, By Treatment Optimization (2021-2030) ($MN)
Table 19 Global In Silico Clinical Trials Market Outlook, By Medical Devices (2021-2030) ($MN)
Table 20 Global In Silico Clinical Trials Market Outlook, By Regulatory Approval (2021-2030) ($MN)
Table 21 Global In Silico Clinical Trials Market Outlook, By End User (2021-2030) ($MN)
Table 22 Global In Silico Clinical Trials Market Outlook, By Pharmaceutical and Biotechnology Companies (2021-2030) ($MN)
Table 23 Global In Silico Clinical Trials Market Outlook, By Contract Research Organizations (2021-2030) ($MN)
Table 24 Global In Silico Clinical Trials Market Outlook, By Academic and Research Institutes (2021-2030) ($MN)
Table 25 Global In Silico Clinical Trials Market Outlook, By Other End Users (2021-2030) ($MN)
Table 26 North America In Silico Clinical Trials Market Outlook, By Country (2021-2030) ($MN)
Table 27 North America In Silico Clinical Trials Market Outlook, By Therapeutic Area (2021-2030) ($MN)
Table 28 North America In Silico Clinical Trials Market Outlook, By Oncology (2021-2030) ($MN)
Table 29 North America In Silico Clinical Trials Market Outlook, By Cardiology (2021-2030) ($MN)
Table 30 North America In Silico Clinical Trials Market Outlook, By Diabetes (2021-2030) ($MN)
Table 31 North America In Silico Clinical Trials Market Outlook, By Infectious Disease (2021-2030) ($MN)
Table 32 North America In Silico Clinical Trials Market Outlook, By Neurology (2021-2030) ($MN)
Table 33 North America In Silico Clinical Trials Market Outlook, By Hematology (2021-2030) ($MN)
Table 34 North America In Silico Clinical Trials Market Outlook, By Dermatology (2021-2030) ($MN)
Table 35 North America In Silico Clinical Trials Market Outlook, By Other Therapeutic Areas (2021-2030) ($MN)
Table 36 North America In Silico Clinical Trials Market Outlook, By Phase (2021-2030) ($MN)
Table 37 North America In Silico Clinical Trials Market Outlook, By Phase I (2021-2030) ($MN)
Table 38 North America In Silico Clinical Trials Market Outlook, By Phase II (2021-2030) ($MN)
Table 39 North America In Silico Clinical Trials Market Outlook, By Phase III (2021-2030) ($MN)
Table 40 North America In Silico Clinical Trials Market Outlook, By Phase IV (2021-2030) ($MN)
Table 41 North America In Silico Clinical Trials Market Outlook, By Application (2021-2030) ($MN)
Table 42 North America In Silico Clinical Trials Market Outlook, By Drug Development (2021-2030) ($MN)
Table 43 North America In Silico Clinical Trials Market Outlook, By Treatment Optimization (2021-2030) ($MN)
Table 44 North America In Silico Clinical Trials Market Outlook, By Medical Devices (2021-2030) ($MN)
Table 45 North America In Silico Clinical Trials Market Outlook, By Regulatory Approval (2021-2030) ($MN)
Table 46 North America In Silico Clinical Trials Market Outlook, By End User (2021-2030) ($MN)
Table 47 North America In Silico Clinical Trials Market Outlook, By Pharmaceutical and Biotechnology Companies (2021-2030) ($MN)
Table 48 North America In Silico Clinical Trials Market Outlook, By Contract Research Organizations (2021-2030) ($MN)
Table 49 North America In Silico Clinical Trials Market Outlook, By Academic and Research Institutes (2021-2030) ($MN)
Table 50 North America In Silico Clinical Trials Market Outlook, By Other End Users (2021-2030) ($MN)
Table 51 Europe In Silico Clinical Trials Market Outlook, By Country (2021-2030) ($MN)
Table 52 Europe In Silico Clinical Trials Market Outlook, By Therapeutic Area (2021-2030) ($MN)
Table 53 Europe In Silico Clinical Trials Market Outlook, By Oncology (2021-2030) ($MN)
Table 54 Europe In Silico Clinical Trials Market Outlook, By Cardiology (2021-2030) ($MN)
Table 55 Europe In Silico Clinical Trials Market Outlook, By Diabetes (2021-2030) ($MN)
Table 56 Europe In Silico Clinical Trials Market Outlook, By Infectious Disease (2021-2030) ($MN)
Table 57 Europe In Silico Clinical Trials Market Outlook, By Neurology (2021-2030) ($MN)
Table 58 Europe In Silico Clinical Trials Market Outlook, By Hematology (2021-2030) ($MN)
Table 59 Europe In Silico Clinical Trials Market Outlook, By Dermatology (2021-2030) ($MN)
Table 60 Europe In Silico Clinical Trials Market Outlook, By Other Therapeutic Areas (2021-2030) ($MN)
Table 61 Europe In Silico Clinical Trials Market Outlook, By Phase (2021-2030) ($MN)
Table 62 Europe In Silico Clinical Trials Market Outlook, By Phase I (2021-2030) ($MN)
Table 63 Europe In Silico Clinical Trials Market Outlook, By Phase II (2021-2030) ($MN)
Table 64 Europe In Silico Clinical Trials Market Outlook, By Phase III (2021-2030) ($MN)
Table 65 Europe In Silico Clinical Trials Market Outlook, By Phase IV (2021-2030) ($MN)
Table 66 Europe In Silico Clinical Trials Market Outlook, By Application (2021-2030) ($MN)
Table 67 Europe In Silico Clinical Trials Market Outlook, By Drug Development (2021-2030) ($MN)
Table 68 Europe In Silico Clinical Trials Market Outlook, By Treatment Optimization (2021-2030) ($MN)
Table 69 Europe In Silico Clinical Trials Market Outlook, By Medical Devices (2021-2030) ($MN)
Table 70 Europe In Silico Clinical Trials Market Outlook, By Regulatory Approval (2021-2030) ($MN)
Table 71 Europe In Silico Clinical Trials Market Outlook, By End User (2021-2030) ($MN)
Table 72 Europe In Silico Clinical Trials Market Outlook, By Pharmaceutical and Biotechnology Companies (2021-2030) ($MN)
Table 73 Europe In Silico Clinical Trials Market Outlook, By Contract Research Organizations (2021-2030) ($MN)
Table 74 Europe In Silico Clinical Trials Market Outlook, By Academic and Research Institutes (2021-2030) ($MN)
Table 75 Europe In Silico Clinical Trials Market Outlook, By Other End Users (2021-2030) ($MN)
Table 76 Asia Pacific In Silico Clinical Trials Market Outlook, By Country (2021-2030) ($MN)
Table 77 Asia Pacific In Silico Clinical Trials Market Outlook, By Therapeutic Area (2021-2030) ($MN)
Table 78 Asia Pacific In Silico Clinical Trials Market Outlook, By Oncology (2021-2030) ($MN)
Table 79 Asia Pacific In Silico Clinical Trials Market Outlook, By Cardiology (2021-2030) ($MN)
Table 80 Asia Pacific In Silico Clinical Trials Market Outlook, By Diabetes (2021-2030) ($MN)
Table 81 Asia Pacific In Silico Clinical Trials Market Outlook, By Infectious Disease (2021-2030) ($MN)
Table 82 Asia Pacific In Silico Clinical Trials Market Outlook, By Neurology (2021-2030) ($MN)
Table 83 Asia Pacific In Silico Clinical Trials Market Outlook, By Hematology (2021-2030) ($MN)
Table 84 Asia Pacific In Silico Clinical Trials Market Outlook, By Dermatology (2021-2030) ($MN)
Table 85 Asia Pacific In Silico Clinical Trials Market Outlook, By Other Therapeutic Areas (2021-2030) ($MN)
Table 86 Asia Pacific In Silico Clinical Trials Market Outlook, By Phase (2021-2030) ($MN)
Table 87 Asia Pacific In Silico Clinical Trials Market Outlook, By Phase I (2021-2030) ($MN)
Table 88 Asia Pacific In Silico Clinical Trials Market Outlook, By Phase II (2021-2030) ($MN)
Table 89 Asia Pacific In Silico Clinical Trials Market Outlook, By Phase III (2021-2030) ($MN)
Table 90 Asia Pacific In Silico Clinical Trials Market Outlook, By Phase IV (2021-2030) ($MN)
Table 91 Asia Pacific In Silico Clinical Trials Market Outlook, By Application (2021-2030) ($MN)
Table 92 Asia Pacific In Silico Clinical Trials Market Outlook, By Drug Development (2021-2030) ($MN)
Table 93 Asia Pacific In Silico Clinical Trials Market Outlook, By Treatment Optimization (2021-2030) ($MN)
Table 94 Asia Pacific In Silico Clinical Trials Market Outlook, By Medical Devices (2021-2030) ($MN)
Table 95 Asia Pacific In Silico Clinical Trials Market Outlook, By Regulatory Approval (2021-2030) ($MN)
Table 96 Asia Pacific In Silico Clinical Trials Market Outlook, By End User (2021-2030) ($MN)
Table 97 Asia Pacific In Silico Clinical Trials Market Outlook, By Pharmaceutical and Biotechnology Companies (2021-2030) ($MN)
Table 98 Asia Pacific In Silico Clinical Trials Market Outlook, By Contract Research Organizations (2021-2030) ($MN)
Table 99 Asia Pacific In Silico Clinical Trials Market Outlook, By Academic and Research Institutes (2021-2030) ($MN)
Table 100 Asia Pacific In Silico Clinical Trials Market Outlook, By Other End Users (2021-2030) ($MN)
Table 101 South America In Silico Clinical Trials Market Outlook, By Country (2021-2030) ($MN)
Table 102 South America In Silico Clinical Trials Market Outlook, By Therapeutic Area (2021-2030) ($MN)
Table 103 South America In Silico Clinical Trials Market Outlook, By Oncology (2021-2030) ($MN)
Table 104 South America In Silico Clinical Trials Market Outlook, By Cardiology (2021-2030) ($MN)
Table 105 South America In Silico Clinical Trials Market Outlook, By Diabetes (2021-2030) ($MN)
Table 106 South America In Silico Clinical Trials Market Outlook, By Infectious Disease (2021-2030) ($MN)
Table 107 South America In Silico Clinical Trials Market Outlook, By Neurology (2021-2030) ($MN)
Table 108 South America In Silico Clinical Trials Market Outlook, By Hematology (2021-2030) ($MN)
Table 109 South America In Silico Clinical Trials Market Outlook, By Dermatology (2021-2030) ($MN)
Table 110 South America In Silico Clinical Trials Market Outlook, By Other Therapeutic Areas (2021-2030) ($MN)
Table 111 South America In Silico Clinical Trials Market Outlook, By Phase (2021-2030) ($MN)
Table 112 South America In Silico Clinical Trials Market Outlook, By Phase I (2021-2030) ($MN)
Table 113 South America In Silico Clinical Trials Market Outlook, By Phase II (2021-2030) ($MN)
Table 114 South America In Silico Clinical Trials Market Outlook, By Phase III (2021-2030) ($MN)
Table 115 South America In Silico Clinical Trials Market Outlook, By Phase IV (2021-2030) ($MN)
Table 116 South America In Silico Clinical Trials Market Outlook, By Application (2021-2030) ($MN)
Table 117 South America In Silico Clinical Trials Market Outlook, By Drug Development (2021-2030) ($MN)
Table 118 South America In Silico Clinical Trials Market Outlook, By Treatment Optimization (2021-2030) ($MN)
Table 119 South America In Silico Clinical Trials Market Outlook, By Medical Devices (2021-2030) ($MN)
Table 120 South America In Silico Clinical Trials Market Outlook, By Regulatory Approval (2021-2030) ($MN)
Table 121 South America In Silico Clinical Trials Market Outlook, By End User (2021-2030) ($MN)
Table 122 South America In Silico Clinical Trials Market Outlook, By Pharmaceutical and Biotechnology Companies (2021-2030) ($MN)
Table 123 South America In Silico Clinical Trials Market Outlook, By Contract Research Organizations (2021-2030) ($MN)
Table 124 South America In Silico Clinical Trials Market Outlook, By Academic and Research Institutes (2021-2030) ($MN)
Table 125 South America In Silico Clinical Trials Market Outlook, By Other End Users (2021-2030) ($MN)
Table 126 Middle East & Africa In Silico Clinical Trials Market Outlook, By Country (2021-2030) ($MN)
Table 127 Middle East & Africa In Silico Clinical Trials Market Outlook, By Therapeutic Area (2021-2030) ($MN)
Table 128 Middle East & Africa In Silico Clinical Trials Market Outlook, By Oncology (2021-2030) ($MN)
Table 129 Middle East & Africa In Silico Clinical Trials Market Outlook, By Cardiology (2021-2030) ($MN)
Table 130 Middle East & Africa In Silico Clinical Trials Market Outlook, By Diabetes (2021-2030) ($MN)
Table 131 Middle East & Africa In Silico Clinical Trials Market Outlook, By Infectious Disease (2021-2030) ($MN)
Table 132 Middle East & Africa In Silico Clinical Trials Market Outlook, By Neurology (2021-2030) ($MN)
Table 133 Middle East & Africa In Silico Clinical Trials Market Outlook, By Hematology (2021-2030) ($MN)
Table 134 Middle East & Africa In Silico Clinical Trials Market Outlook, By Dermatology (2021-2030) ($MN)
Table 135 Middle East & Africa In Silico Clinical Trials Market Outlook, By Other Therapeutic Areas (2021-2030) ($MN)
Table 136 Middle East & Africa In Silico Clinical Trials Market Outlook, By Phase (2021-2030) ($MN)
Table 137 Middle East & Africa In Silico Clinical Trials Market Outlook, By Phase I (2021-2030) ($MN)
Table 138 Middle East & Africa In Silico Clinical Trials Market Outlook, By Phase II (2021-2030) ($MN)
Table 139 Middle East & Africa In Silico Clinical Trials Market Outlook, By Phase III (2021-2030) ($MN)
Table 140 Middle East & Africa In Silico Clinical Trials Market Outlook, By Phase IV (2021-2030) ($MN)
Table 141 Middle East & Africa In Silico Clinical Trials Market Outlook, By Application (2021-2030) ($MN)
Table 142 Middle East & Africa In Silico Clinical Trials Market Outlook, By Drug Development (2021-2030) ($MN)
Table 143 Middle East & Africa In Silico Clinical Trials Market Outlook, By Treatment Optimization (2021-2030) ($MN)
Table 144 Middle East & Africa In Silico Clinical Trials Market Outlook, By Medical Devices (2021-2030) ($MN)
Table 145 Middle East & Africa In Silico Clinical Trials Market Outlook, By Regulatory Approval (2021-2030) ($MN)
Table 146 Middle East & Africa In Silico Clinical Trials Market Outlook, By End User (2021-2030) ($MN)
Table 147 Middle East & Africa In Silico Clinical Trials Market Outlook, By Pharmaceutical and Biotechnology Companies (2021-2030) ($MN)
Table 148 Middle East & Africa In Silico Clinical Trials Market Outlook, By Contract Research Organizations (2021-2030) ($MN)
Table 149 Middle East & Africa In Silico Clinical Trials Market Outlook, By Academic and Research Institutes (2021-2030) ($MN)
Table 150 Middle East & Africa In Silico Clinical Trials Market Outlook, By Other End Users (2021-2030) ($MN)

Product Code: SMRC24210

According to Stratistics MRC, the Global In Silico Clinical Trials Market is accounted for $3.23 billion in 2023 and is expected to reach $6.06 billion by 2030 growing at a CAGR of 9.4% during the forecast period. In silico clinical trials, also known as virtual or computational clinical trials, are a form of computer-based modeling and simulation used in the pharmaceutical and healthcare industries. They involve the use of computational techniques and mathematical models to simulate various aspects of clinical trials, drug development, and patient responses to medications. In silico clinical trials aim to reduce the need for extensive and costly physical trials, accelerate drug development, optimize treatment strategies, and enhance patient safety by providing valuable insights before advancing to human or animal testing.

According to the European Medicines Agency - European Union, in the EU / EEA, more than 4,000 clinical trials are authorised each year, of which 60% of clinical trials are sponsored by the pharma industry and 40% by non-commercial sponsors.

Market Dynamics:

Driver:

Improved patient safety

In silico trials offer a transformative approach to drug development by replacing or supplementing traditional human trials with computer simulations. This method significantly reduces the risks associated with experimental drug testing on human subjects. In silico studies improve the safety profile of novel drug candidates by enabling the evaluation of possible side effects, drug interactions, and patient-specific responses through the use of virtual patient models. Furthermore, these trials enable pharmaceutical companies to refine drug formulations and optimise dosages to minimise side effects and ensure a higher level of safety for patients. As patient safety is a paramount concern in the pharmaceutical industry, in silico clinical trials provide a powerful avenue for enhancing the overall safety of drug development processes, making them a pivotal driver in the market's growth and adoption.

Restraint:

Interdisciplinary challenges

Interdisciplinary challenges serve as a significant restraint in the in silico clinical trial market. In silico trials require collaboration between experts from diverse fields, including biology, chemistry, pharmacology, data science, and computer engineering. Effective communication and integration of knowledge from these disciplines can be complex, potentially leading to misinterpretations, data incompatibility, or misunderstandings. These interdisciplinary challenges may slow down research and development efforts, hinder the adoption of in silico methods, and necessitate enhanced coordination and standardisation to unlock the full potential of this innovative approach in drug development.

Opportunity:

Advancements in artificial intelligence and machine learning technologies

Advancements in artificial intelligence (AI) and machine learning (ML) technologies present a significant opportunity in the in silico clinical trials market. These technologies enhance the precision of in silico clinical trials by predicting patient responses, optimising drug candidates, and identifying potential adverse effects. Furthermore, AI and machine learning empower the discovery of new therapeutic targets and the repurposing of existing drugs, reducing the time and cost required for research. As these technologies continue to evolve, the in silico clinical trials market stands to benefit from increased efficiency, improved success rates in drug development, and the potential for more tailored and effective treatments, ultimately revolutionising the pharmaceutical industry.

Threat:

Lack of standardized protocols and regulatory frameworks

In silico trials rely on computational models and simulations, and the absence of universally accepted standards can lead to variability and inconsistency in the results. Moreover, regulatory bodies may struggle to establish clear guidelines for evaluating and approving in silico trials, potentially delaying their adoption. The lack of standardised protocols and regulations raises concerns about the credibility and reliability of in silico trial outcomes, hindering trust and acceptance within the pharmaceutical and healthcare industries.

COVID-19 Impact

The COVID-19 pandemic crisis had a devastating effect on several industries. The use of computers to aid in drug development during this time led to a notable increase in the in-silico trial market. Because academics and biotechnological and biopharmaceutical businesses are working intensively on R&D for preventing the coronavirus disease from spreading, there is a greater need for in silico trials that use computational modelling. Furthermore, Scientists are working hard to find a cure for the COVID-19 pandemic as a result of the virus' rising mutation rate. As a result, the importance of research and drug discovery was increased, which in turn fueled the rise of the in silico computational modelling and simulation trials for medical product innovation and regulatory clearance.

The Oncology segment is expected to be the largest during the forecast period

The Oncology segment is estimated to hold the largest share. In silico clinical trials offer a groundbreaking approach to oncology research by utilising computer simulations and modelling to accelerate the development of cancer treatments. These simulations help assess drug candidates' efficacy, predict patient responses, and optimise treatment strategies. Given the complexity of cancer and the urgency for innovative therapies, in silico clinical trials in oncology offer significant advantages in terms of cost and time savings, as well as reduced risks associated with traditional clinical trials. This segment plays a pivotal role in advancing precision medicine and personalised cancer treatments, offering hope for improved outcomes for cancer patients.

The Pharmaceutical and Biotechnology Companies segment is expected to have the highest CAGR during the forecast period

The Pharmaceutical and Biotechnology Companies segment is anticipated to have lucrative growth during the forecast period. Pharmaceutical and biotechnology companies utilise in silico methods to streamline drug discovery and development processes. In silico trials employ computer simulations and modelling to predict drug behaviour, optimise formulations, and assess safety and efficacy. This approach significantly reduces research and development costs and expedites the time it takes to bring new drugs to market. It also enables a more efficient exploration of drug candidates, minimising the need for costly and time-consuming physical trials. Moreover, Pharmaceutical and biotechnology companies leverage in silico clinical trials to enhance their research pipelines, increase innovation, and ultimately deliver safer and more effective therapies to patients.

Region with largest share:

Asia Pacific commanded the largest market share during the extrapolated period. Factors driving this growth include a robust pharmaceutical and biotechnology industry, a large and diverse patient population, and a supportive regulatory environment. In silico clinical trials, which utilise computer simulations and modelling to assess drug efficacy and safety, offer cost-effective and efficient alternatives to traditional clinical trials. This approach not only accelerates the drug development process but also reduces costs and the ethical concerns associated with human trials. The Asia-Pacific region's increasing investment in this technology highlights its potential to become a key hub for in silico clinical trials, contributing to faster drug development and improved healthcare outcomes.

Region with highest CAGR:

North America is expected to witness profitable growth over the projection period. North America is a prominent hub in the in silico clinical trials market. The region boasts a well-established pharmaceutical and biotechnology sector, which continually seeks innovative solutions to expedite drug development. In silico clinical trials, which utilise computer-based simulations to assess drug safety and efficacy, are gaining traction due to their cost-efficiency and speed. The presence of major pharmaceutical companies and cutting-edge research institutions further drives the adoption of this technology. Additionally, North America's regulatory framework and healthcare infrastructure support the growth of in silico clinical trials, positioning the region as a leader in advancing drug discovery and development through computational modelling and simulations.

Key players in the market

Some of the key players in the In Silico Clinical Trials Market include: Certara, Inc., Insilico Medicine, Inc., Novadiscovery Sas, Dassault Systemes SE, The AnyLogic Company, GNS Healthcare Inc., InSilicoTrials, Nuventra Pharma Sciences, Immunetrics Inc., Abzena Ltd., Clarivate, Evotec, Aitia, Allucent and Acellera Ltd.

Key Developments:

In March 2022, QuantHealth partnered with 4P-Pharma to conduct AI-based in-Silico clinical trial simulations. In collaboration, the partnership would perform in silico clinical trials of their lead therapeutic candidates. The in-silico simulation of the phase II clinical trial of 4P004, a first-in-class disease-modifying osteoarthritis medication (DMOAD) developed by 4PPharma's spin-off, would kick off this comprehensive alliance.

In February 2022, IonsGate Preclinical Services and InSilicoTrials teamed up to revolutionize drug development. To digitalize IonsGate's drug development methods, InSilicoTrials would deliver a sophisticated modeling and simulation technology. This would reduce the cost and duration of preclinical testing while improving the safety of novel compounds.

Therapeutic Areas Covered:

Oncology
Cardiology
Diabetes
Infectious Disease
Neurology
Hematology
Dermatology
Other Therapeutic Areas

Phases Covered:

Phase I
Phase II
Phase III
Phase IV

Applications Covered:

Drug Development
Treatment Optimization
Medical Devices
Regulatory Approval

End Users Covered:

Pharmaceutical and Biotechnology Companies
Contract Research Organizations
Academic and Research Institutes
Other End Users

Regions Covered:

North America
- US
- Canada
- Mexico
Europe
- Germany
- UK
- Italy
- France
- Spain
- Rest of Europe
Asia Pacific
- Japan
- China
- India
- Australia
- New Zealand
- South Korea
- Rest of Asia Pacific
South America
- Argentina
- Brazil
- Chile
- Rest of South America
Middle East & Africa
- Saudi Arabia
- UAE
- Qatar
- South Africa
- Rest of Middle East & Africa

What our report offers:

Market share assessments for the regional and country-level segments
Strategic recommendations for the new entrants
Covers Market data for the years 2021, 2022, 2023, 2026, and 2030
Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
Strategic recommendations in key business segments based on the market estimations
Competitive landscaping mapping the key common trends
Company profiling with detailed strategies, financials, and recent developments
Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

Company Profiling
- Comprehensive profiling of additional market players (up to 3)
- SWOT Analysis of key players (up to 3)
Regional Segmentation
- Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
Competitive Benchmarking
- Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

1 Executive Summary

2 Preface

2.1 Abstract
2.2 Stake Holders
2.3 Research Scope
2.4 Research Methodology
- 2.4.1 Data Mining
- 2.4.2 Data Analysis
- 2.4.3 Data Validation
- 2.4.4 Research Approach
2.5 Research Sources
- 2.5.1 Primary Research Sources
- 2.5.2 Secondary Research Sources
- 2.5.3 Assumptions

3 Market Trend Analysis

3.1 Introduction
3.2 Drivers
3.3 Restraints
3.4 Opportunities
3.5 Threats
3.6 Application Analysis
3.7 End User Analysis
3.8 Emerging Markets
3.9 Impact of Covid-19

4 Porters Five Force Analysis

4.1 Bargaining power of suppliers
4.2 Bargaining power of buyers
4.3 Threat of substitutes
4.4 Threat of new entrants
4.5 Competitive rivalry

5 Global In Silico Clinical Trials Market, By Therapeutic Area

5.1 Introduction
5.2 Oncology
5.3 Cardiology
5.4 Diabetes
5.5 Infectious Disease
5.6 Neurology
5.7 Hematology
5.8 Dermatology
5.9 Other Therapeutic Areas

6 Global In Silico Clinical Trials Market, By Phase

6.1 Introduction
6.2 Phase I
6.3 Phase II
6.4 Phase III
6.5 Phase IV

7 Global In Silico Clinical Trials Market, By Application

7.1 Introduction
7.2 Drug Development
7.3 Treatment Optimization
7.4 Medical Devices
7.5 Regulatory Approval

8 Global In Silico Clinical Trials Market, By End User

8.1 Introduction
8.2 Pharmaceutical and Biotechnology Companies
8.3 Contract Research Organizations
8.4 Academic and Research Institutes
8.5 Other End Users

9 Global In Silico Clinical Trials Market, By Geography

9.1 Introduction
9.2 North America
- 9.2.1 US
- 9.2.2 Canada
- 9.2.3 Mexico
9.3 Europe
- 9.3.1 Germany
- 9.3.2 UK
- 9.3.3 Italy
- 9.3.4 France
- 9.3.5 Spain
- 9.3.6 Rest of Europe
9.4 Asia Pacific
- 9.4.1 Japan
- 9.4.2 China
- 9.4.3 India
- 9.4.4 Australia
- 9.4.5 New Zealand
- 9.4.6 South Korea
- 9.4.7 Rest of Asia Pacific
9.5 South America
- 9.5.1 Argentina
- 9.5.2 Brazil
- 9.5.3 Chile
- 9.5.4 Rest of South America
9.6 Middle East & Africa
- 9.6.1 Saudi Arabia
- 9.6.2 UAE
- 9.6.3 Qatar
- 9.6.4 South Africa
- 9.6.5 Rest of Middle East & Africa

10 Key Developments

10.1 Agreements, Partnerships, Collaborations and Joint Ventures
10.2 Acquisitions & Mergers
10.3 New Product Launch
10.4 Expansions
10.5 Other Key Strategies

11 Company Profiling

11.1 Certara, Inc.
11.2 Insilico Medicine, Inc.
11.3 Novadiscovery Sas
11.4 Dassault Systemes SE
11.5 The AnyLogic Company
11.6 GNS Healthcare Inc.
11.7 InSilicoTrials
11.8 Nuventra Pharma Sciences
11.9 Immunetrics Inc.
11.10 Abzena Ltd.
11.11 Clarivate
11.12 Evotec
11.13 Aitia
11.14 Allucent
11.15 Acellera Ltd.